Pia Grundschöttel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pia Grundschöttel has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Alexander Goihl
Institute of Molecular and Clinical Immunology, Otto-von-Guericke-University, Magdeburg, Germany
1 shared publicationAlvaro Domingues-Baquero
German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany
1 shared publication- Andrew G. Newman
Institute of Cell and Neurobiology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany
1 shared publication - Anja Schneider
Department of Old Age Psychiatry and Cognitive Disorders, University Hospital Bonn, Bonn, Germany
1 shared publication - Benjamin Rainer Rost
German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany
1 shared publication - Bilge Askin
German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany
1 shared publication
Latest Publications
- Open Access
- 15 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (20) , eaec2042
IgLON5 autoimmune antibodies activate Tau via neuronal hyperactivity
Anti-IgLON5 disease is an autoimmune disease, in which autoantibodies (AABs) against the neuronal cell surface protein IgLON5 lead to profound brain dysfunction and Tau pathology. How α-IgLON5 AABs cause neuronal Tau protein pathology and neurodegeneration remains unclear. We find that patient-derived α-IgLON5 AABs cluster IgLON5 proteins with other cell surface proteins, leading to neuronal hyperactivity that triggers pathological Tau missorting and phosphorylation, typically observed early in Tau-related neurodegenerative diseases. In wild-type mice, α-IgLON5 AABs induce hippocampal Tau phosphorylation and neuroinflammatory responses. Our findings establish a causal link between the α-IgLON5 AABs and Tau pathology in anti-IgLON5 disease patients and highlight the role of neuronal hyperactivity as a disease-overarching driver of Tau pathology and provide a potential target for therapeutic intervention.
- 15 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (20) , eaec2042
Open AccessIgLON5 autoimmune antibodies activate Tau via neuronal hyperactivity
Anti-IgLON5 disease is an autoimmune disease, in which autoantibodies (AABs) against the neuronal cell surface protein IgLON5 lead to profound brain dysfunction and Tau pathology. How α-IgLON5 AABs cause neuronal Tau protein pathology and neurodegeneration remains unclear. We find that patient-derived α-IgLON5 AABs cluster IgLON5 proteins with other cell surface proteins, leading to neuronal hyperactivity that triggers pathological Tau missorting and phosphorylation, typically observed early in Tau-related neurodegenerative diseases. In wild-type mice, α-IgLON5 AABs induce hippocampal Tau phosphorylation and neuroinflammatory responses. Our findings establish a causal link between the α-IgLON5 AABs and Tau pathology in anti-IgLON5 disease patients and highlight the role of neuronal hyperactivity as a disease-overarching driver of Tau pathology and provide a potential target for therapeutic intervention.